Pfizer Inc. ($PFE) has sold its stake worth $3.26 billion in UK-based consumer healthcare company Haleon PLC ($GB:HLN). With ...

The study highlighted that 57.7% of neonates in the case group had a diagnosis of neonatal abstinence syndrome compared to 10 ...

Multidisciplinary board members bring expertise in drug discovery, clinical development, computational life science, GPCRs and drug formulationBOSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- , Inc., “The ...

Pfizer is following the example of GlaxoSmithKline and Novartis, two big pharmas that have already appointed chief digital officers to transform R&D and relationships with customers. Last year ...

Pfizer’s plans to duck out of central nervous ... including AstraZeneca, Novartis and GlaxoSmithKline. As a result, there were only 12 CNS therapeutics approved in the 2012-2016 period, down ...

PARP Inhibitor Market is projected to expand substantially, surpassing USD 16,153.50 million by 2034 at a CAGR of 8.70%.

Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Haleon separately said on Monday it had agreed to make an off-market purchase of about 230 million pounds ($308.18 million) ...

Big Pharma is investing heavily in AI to slash development timelines and foster innovation. | Big Pharma is investing heavily ...